The U.S. Food and Drug Administration on Wednesday approved Medtronic’s “artificial pancreas” designed to automatically deliver the right dose of insulin to patients with type 1 diabetes.
The eagerly-awaited approval offers patients “greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin,” Dr. Jeffrey Shuren, director of the FDA’s medical device division said in a statement.
The device, called the MiniMed 670G measures glucose levels every five minutes and automatically administers insulin as needed.
“This device will mean peace of mind, in knowing a person will be in normal blood sugar range a great majority of the time,” said Derek Rapp, Chief Executive Officer of the Juvenile Diabetes Research Foundation, which has spent $116 million on research on the artificial pancreas field.
Read more: St. Louis Post-Dispatch